Would you consider anifrolumab in the management of hematologic manifestations in SLE?
Community PollStarted
Would you consider anifrolumab for management of hematologic manifestations in SLE?
25 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Rheumatology · Hackensack University Medical Center
Answered on
Hematologic manifestations in SLE vary widely from asymptomatic to life-threatening, from cytopenias to severe bleeding to thrombosis to multiorgan failure. Hematologic manifestations can also be compounded by medications, infections, and co-existing conditions. Each of these manifestations is drive...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)
Answered on
I agree with Dr. @Dr. First Last that we are still awaiting more results from the TULIP-1 and TULIP-2 trials on anifrolumab.
However, there is data from the phase II clinical trial, the MUSE trial (Casey et al., PMID 30538817), showing improvements in cytopenias (lymphopenia, neutropenia, and thromb...
Join for free or sign in to see the full answer